Spruce Biosciences

Spruce Biosciences, Inc operates as a late-stage biopharmaceutical company, which focuses on the development of novel therapies for rare diseases affecting the endocrine system. The firm is initially developing its wholly-owned product candidate, tildacerfont, as the non-steroidal therapy to offer markedly improved disease control and reduce steroid burden for patients suffering from classic congenital adrenal hyperplasia. The company was founded on November 13, 2014 and is headquartered in Daly City, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Spruce Biosciences reports mixed trial results, eyes Phase III advancement

Spruce Biosciences faces a mixed performance in Phase II trials, with promising results in pediatric CAH patients but challenges in adult populations. Financially, the company is stable with a focus on cost-saving initiatives. Despite setbacks, opportunities exist in advancing tildacerfont for CAH treatment.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif.--( BUSINESS WIRE )--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).

Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

SOUTH SAN FRANCISCO, Calif. & TOKYO--( BUSINESS WIRE )--Spruce Biosciences, Inc. (Nasdaq: SPRB) and Kaken Pharmaceutical Co. Ltd (Tokyo Stock Exchange: 4521) today announced that the companies have entered into an exclusive licensing agreement for the development and commercialization of Spruce's product candidate, tildacerfont, for the treatment of congenial adrenal hyperplasia (CAH) in Japan.

Spruce Biosciences and Kaken Pharmaceutical Announce Strategic Partnership and Exclusive Licensing Agreement to Develop and Commercialize Tildacerfont for CAH in Japan

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the third quarter ended September 30, 2022 and provided corporate updates.

Spruce Biosciences Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #CAH--Spruce Biosciences to Participate in November Investor Conferences

Spruce Biosciences to Participate in November Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB #Tildacerfont--Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

Spruce Biosciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2022 and provided corporate updates. “Throughout the second quarter of 2022, we continued to remain focused on clinical study execution. We were pleased to have recently surpassed 25% enrollme

Spruce Biosciences Reports Second Quarter 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place in June. Jefferies Healthcare Conference Date: June 8-10, 2022 Format: Company presentation (June 8, 2022 at 4:00pm ET) and 1x1 meetings JMP Securities Life

Spruce Biosciences to Participate in June Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that a submitted abstract was accepted for poster presentation at the 104th Annual Meeting of the Endocrine Society (ENDO 2022) taking place June 11-14, 2022, in Atlanta, GA. In a recorded presentation, the company will highlight results from a re

Spruce Biosciences Announces Acceptance of Abstract for Presentation at ENDO 2022 Annual Conference

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the first quarter ended March 31, 2022 and provided corporate updates. “Throughout the first quarter of 2022, we continued to drive our clinical and business objectives forward, with key progress made in our lead program for a

Spruce Biosciences Reports First Quarter 2022 Financial Results and Provides Corporate Update

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Libbie Mansell, Ph.D., M.B.A., R.A.C., has been appointed Chief Regulatory and Quality Officer. Dr. Mansell will be responsible for leading the company's global regulatory affairs and quality strategy. “Dr. Mansell brings extensive regulatory

Spruce Biosciences Appoints Libbie Mansell, Ph.D., M.B.A., R.A.C.

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “Over the last quarter, we have made notable progress in our efforts to advance new treatment options for people living with rare endocr

Spruce Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Will Charlton, M.D., M.A.S., has been appointed Chief Medical Officer, and will succeed Rosh Dias, M.D., who has stepped down to pursue other opportunities. Dr. Charlton is a board-certified pediatric endocrinologist with over 15 years of cli

Spruce Biosciences Appoints Will Charlton, M.D., M.A.S., as Chief Medical Officer

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that company management will participate in two upcoming investor conferences taking place virtually in March. Cowen 42nd Annual Health Care Conference Date: March 7-9, 2022 Format: Company presentation (March 9 at 11:10 a.m. ET) and 1x1 meetings

Spruce Biosciences to Participate in March Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., MPH, Chief Executive Officer, and Samir Gharib, President and Chief Financial Officer, will participate in a virtual fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17, 2022 at 5:

Spruce Biosciences to Participate in the SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, upcoming milestones and strategic priorities for enhancing the design of and accelerating patient recruitment into the CAHmelia studies, which are evaluating tildacerfont for the treatment of adult classic congen

Spruce Biosciences Provides Clinical Program Updates and Outlook for 2022

The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 13.48% in the most recent trading session. This is why it happened.

Spruce Biosciences Stock (SPRB): Why The Price Jumped

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Dr. Javier Szwarcberg, M.D., MPH, has been appointed Chief Executive Officer and as a member of the board of directors. Samir Gharib, MBA, has been concurrently promoted to President and will continue in his role as Chief Financial Officer. “

Spruce Biosciences Appoints Javier Szwarcberg, M.D., MPH as Chief Executive Officer

Aptose Biosciences

Celularity

CNS Pharmaceuticals

Celyad

Biotech stocks from the Medical sector, including APTO, CELU, CNSP, CYAD and SPRB, might be witnessing a turnaround in 2022 to emerge as solid investment options.

5 Beaten-Down Biotech Bets to Bounce Back in 2022

Future FinTech Group

Nxt-ID

Sino-Global Shipping America

Penny stocks with high short interest gaining plenty of attention in the stock market today. The post Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Short Squeeze Penny Stocks To Buy For Under $5 If You Like Risk

Inspira Technologies Oxy BHN Ltd

Protalix Biotherapeutics

Selecta Biosciences

Tellurian

5 penny stocks with high short interest to add to your watch list in December. The post Best Penny Stocks To Buy?

Best Penny Stocks To Buy? 5 Short Squeeze Stocks To Watch Right Now

The stock price of Spruce Biosciences Inc (NASDAQ: SPRB) increased by 102.82% in the previous trading session. This is why it happened.

Spruce Biosciences Stock (SPRB): Why The Price Surged

Spruce Biosciences, Inc. (SPRB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Spruce Biosciences, Inc. (SPRB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

SAN FRANCISCO--(BUSINESS WIRE)---- $SPRB--Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

SAN FRANCISCO--(BUSINESS WIRE)--Spruce Biosciences Appoints Mike Grey as Interim CEO

News for Spruce Biosciences Stock (SPRB)